Citigroup Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $33
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $33.
Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $33.